

Special Issue

Pharmacology of HIV Treatment and Antivirals Against Hepatitis Viruses

Message from the Guest Editor

Therapies for HIV infection and hepatitis C have significantly evolved in recent years. Newer antiretrovirals have overcome significant obstacles like side effects, high daily pill burden, lack of efficacy, resistances, or limited access to therapy, and now, most patients receive simple therapies, mostly consisting of single-tablet regimens or long-acting injectable drugs, achieving long-lasting virological response.

Furthermore, HIV might also benefit from monoclonal antibodies, which may dramatically change HIV therapy as we currently know. Direct-acting antivirals for hepatitis C infection have radically changed millions of patients' lives worldwide, achieving remarkable efficacy with short, simple treatment regimens. This therapeutic revolution has turned a complex chronic infection with limited treatment options into an eradicable disease, as seen in several population-scale trials. The development of new antivirals for hepatitis B and D offers hope for patients seeking a cure.

This Special Issue aims to provide updated information on new antiretrovirals and antivirals against hepatitis viruses, as well as newer treatment strategies and drug delivery methods.

Guest Editor

Dr. José Vicente Fernández-Montero

Department of Internal Medicine, Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain

Deadline for manuscript submissions

closed (31 May 2025)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/198937

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).